News Search Results
Jan 07, 2026, 15:04 ET LabConnect Establishes New Global Headquarters in Raleigh-Durham Area
Carolina, strengthening its footprint in the rapidly growing Research Triangle region, a leading center for Contract Research Organizations (CROs), biotechnology, and pharmaceutical companies. The new office will serve as a strategic base for executive leadership, commercial, operational, and technology teams
More news about: LabConnect
Jan 07, 2026, 11:00 ET Arbele Receives FDA Orphan Drug Designation for ARB1002, an Anti-CDH17 Antibody-Drug Conjugate for the Treatment of Pancreatic Cancer
SEATTLE, Jan. 7, 2026 /PRNewswire/ -- Arbele, a biotechnology company focused on developing innovative targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation
More news about: Arbele
Jan 07, 2026, 10:30 ET Pramana Pharmaceuticals Awarded USD $1 Million from the Alzheimer's Association
global composition-of-matter IP estate.About Pramana PharmaceuticalsPramana Pharmaceuticals Inc. is a near-term clinical-stage biotechnology company developing next-generation oral small-molecule therapies targeting metabolic signaling pathways across neurodegenerative and cardio-metabolic
More news about: Pramana Pharmaceuticals Inc.
Jan 07, 2026, 10:30 ET Pharmaceutical Microfiltration Market worth $9.94 billion by 2030 | MarketsandMarkets™
(Sweden).Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Jan 07, 2026, 10:06 ET A Microscopic Discovery With Massive Implications: Two Physicians Uncover a New Biological Defense Against Microplastics
SARASOTA, Fla., Jan. 7, 2026 /PRNewswire/ -- Quorum Innovations, a biotechnology company founded by physician-scientists Nicholas T. Monsul, MD, and Eva Ann Berkes, MD, today announced growing scientific, medical, and public-policy momentum behind a breakthrough
More news about: QUORUM INNOVATIONS
Jan 07, 2026, 10:00 ET Inimmune Commences Pivotal Phase 2 Allergy Trial of INI-2004 in Allergic Rhinitis Patients
MISSOULA, Mont., Jan. 7, 2026 /PRNewswire/ -- Inimmune Corporation ("Inimmune"), a clinical-stage biotechnology company focused on developing innovative immunotherapies, today announced the start of its pivotal Phase 2 clinical trial evaluating INI-2004 in
More news about: Inimmune Corporation
Jan 07, 2026, 09:07 ET KilgourMD Announces Exclusive Partnership With N1 Life to Bring Peptide-Based Delivery Technology to Scalp Health
/PRNewswire/ -- KilgourMD, known for its clinically-backed approach to scalp health, announced an exclusive partnership with N1 Life, a Stanford spinout biotechnology company pioneering a next-generation peptide carrier platform designed to dramatically enhance the penetration, solubility, and performance of topical
More news about: KilgourMD
Jan 07, 2026, 09:00 ET ProGro BIO Releases New Independent Research
time and again: when the soil performs better, the entire system performs better."About ProGro BIO: ProGro BIO is an agricultural biotechnology company committed to improving soil health, nutrient efficiency, and crop performance through advanced microbial technologies. Rhizol® is designed
More news about: ProGro BIO Inc.
Jan 07, 2026, 08:55 ET Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
clinical trials and product development programs; difficulties or delays in obtaining regulatory approval; competition from other pharmaceutical or biotechnology companies; market volatility affecting our investment portfolio; our ability to realize expected returns from Scilex and other investments; and
More news about: Oramed Pharmaceuticals Inc.
Jan 07, 2026, 08:50 ET Aspen Neuroscience Appoints Chief Commercial Officer Lisa Johnson-Pratt, M.D. and Welcomes Revati Shreeniwas, M.D., FCCP as Chief Medical Officer to Accelerate Late‑Stage Development and Commercial Readiness
SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical‑stage biotechnology company pioneering autologous regenerative therapies, today announced two executive leadership appointments: Revati Shreeniwas, M.D., FCCP has joined
More news about: Aspen Neuroscience, Inc.
Jan 07, 2026, 08:45 ET Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
LEXINGTON, Mass., Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that
More news about: Curis, Inc.
Jan 07, 2026, 08:31 ET TheWell Bioscience and PeptiGrowth Enter into Marketing Collaboration Agreement to Advance Next-Generation Cell Culture Solutions
MONMOUTH JUNCTION, N.J. and TOKYO, Jan. 7, 2026 /PRNewswire/ -- TheWell Bioscience Inc., a biotechnology company pioneering next-generation animal-free biofunctional hydrogels, and PeptiGrowth Inc., a leader in innovative synthetic peptide growth
More news about: TheWell Bioscience
Jan 07, 2026, 08:30 ET Navigating the Animal Rule in Drug Development with Modeling & Simulation, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jan 07, 2026, 08:30 ET Bridging Bench to Bedside: De‑Risking Biotherapeutic Administration via CDMO‑Led Clinical‑Mimic and In‑Use Testing Strategies, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jan 07, 2026, 08:30 ET The Power of Less: Winning with Asset-Light Manufacturing, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jan 07, 2026, 08:05 ET Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference
Calif., Jan. 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company
More news about: Rigel Pharmaceuticals, Inc.
Jan 07, 2026, 08:00 ET STRM.BIO Raises $8 Million in Series Seed 2 Financing to Advance Non-Viral Gene Delivery Platform for In Vivo Cell Engineering and Gene Therapy
STRM.BIO, a biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced $8 million in Series Seed 2 financing.
More news about: STRM.BIO
Jan 07, 2026, 07:33 ET GreenWay Herbal Products, LLC awarded a U.S. patent covering a 1-to-1 cannabidiol and cannabidiolic acid cannabinoid composition
business strategies. These include advancing pharmaceutical development efforts and pursuing strategic licensing partnerships with pharmaceutical, biotechnology and specialty health companies. The company is also evaluating opportunities where its patented cannabinoid composition could be combined with advanced
More news about: GreenWay Herbal Products, LLC
Jan 07, 2026, 07:33 ET Rakuten Medical Raises $100 Million in Oversubscribed Series F to Accelerate Development Toward U.S. Regulatory Approval
investorsSAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing its proprietary Alluminox® platform-based photoimmunotherapy, today announced the closing of a
More news about: Rakuten Medical, Inc.
Jan 07, 2026, 07:30 ET Cytora Therapeutics, Made Scientific, and Zeo ScientifiX Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States
TEL AVIV, Israel, Jan. 7, 2026 /PRNewswire/ -- Cytora Therapeutics Ltd. (Cytora), a clinical-stage biotechnology company based in Israel developing allogeneic, stem cell therapies; Made Scientific, Inc. (Made Scientific), a leading U.S.-based cell therapy contract
More news about: Made Scientific, Inc.; Cytora
Jan 07, 2026, 07:00 ET Nanoscope Therapeutics Granted New U.S. Patent Covering Its Proprietary Multi-Characteristic Opsin Platform for Vision Restoration
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Jan 07, 2026, 07:00 ET Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio
Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced an oversubscribed $76 million Series B financing co-led by
More news about: Mediar Therapeutics
Jan 07, 2026, 06:30 ET Immunic Highlights 2025 Accomplishments and Upcoming Milestones
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today highlighted its 2025 accomplishments
More news about: Immunic, Inc.
Jan 07, 2026, 03:30 ET AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board
Seasoned executive with extensive board experience across US and European biotechnology companiesBrings extensive operational, strategic and transactional expertise as AstronauTx advances its innovative pipeline targeting improvements in sleep architecture to
More news about: AstronauTx
Jan 07, 2026, 03:30 ET Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs
more at www.lonza.com.About Synaffix Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect®, HydraSpace®
More news about: Synaffix